|
|
Baxter International Inc (NYSE: BAX) |
|
|
|
|
|
Baxter International Inc's Suppliers Performance
BAX's Supply Chain
| |
|
BAX Costs vs Sales of Suppliers Growth |
Baxter International Inc's Suppliers recorded an increase in sales by 0.81 % year on year in Q1 2025, from the previous quarter, sales fell by -2.13 %, Baxter International Inc's cost of sales deteriorated by -20 % year on year, sequentially cost of sales grew by 341 % in Q1.
•
More on BAX Suppliers
|
|
|
Baxter International Inc's Suppliers recorded an increase in sales by 0.81 % year on year in Q1 2025, from the previous quarter, sales fell by -2.13 %, Baxter International Inc's cost of sales deteriorated by -20 % year on year, sequentially cost of sales grew by 341 % in Q1.
•
More on BAX Suppliers
|
Select the Relationship:
|
|
Select the Category:
|
|
Baxter International Inc's Comment on Supply Chain
|
BAX's Suppliers Net Income grew by |
BAX's Suppliers Net margin grew in Q1 to |
|
21.45 % |
4.7 % |
|
BAX's Suppliers Net Income grew by 21.45 % |
BAX's Suppliers Net margin grew in Q1 to 4.7 % |
BAX's vs. Suppliers, Data
(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)
| COMPANY NAME |
MARKET CAP |
REVENUES |
INCOME |
EMPLOYEES |
|
Baxter International Inc
|
14,273.78 |
9,669.00 |
-551.00 |
41,000 |
|
Abbott Laboratories
|
216,078.70 |
42,344.00 |
13,502.00 |
114,000 |
|
|
|
Piedmont Lithium Inc
|
172.22 |
107.18 |
-56.78 |
13 |
|
|
|
Cardinal Health Inc
|
38,453.96 |
222,127.00 |
1,560.00 |
48,900 |
|
The factor of 0.243 indicates a mild correlation between Cardinal Health Inc 's revenue and those of Baxter International Inc . |
|
Ati Inc
|
13,523.54 |
4,464.10 |
414.80 |
7,300 |
|
|
|
Thermo Fisher Scientific Inc
|
157,190.25 |
42,898.00 |
6,518.00 |
122,000 |
|
|
|
Astrotech Corp
|
9.17 |
1.98 |
-14.15 |
30 |
|
The factor of 0.201 indicates a mild correlation between Astrotech Corp's revenue and those of Baxter International Inc . |
|
Cryoport inc
|
359.12 |
214.83 |
-115.84 |
31 |
|
A negative correlation coefficient of -0.014 implies that the revenue of Cryoport inc does not correlate significantly with that of Baxter International Inc . |
|
Haynes International inc
|
785.80 |
613.50 |
37.51 |
900 |
|
A negative correlation coefficient of -0.207 implies that the revenue of Haynes International inc does not correlate significantly with that of Baxter International Inc . |
|
Universal Stainless and Alloy Products Inc
|
447.32 |
325.47 |
26.65 |
622 |
|
|
|
Forward Industries Inc
|
10.13 |
24.95 |
-3.20 |
29 |
|
The factor of 0.278 indicates a mild correlation between Forward Industries Inc 's revenue and those of Baxter International Inc . |
|
Ufp Technologies Inc
|
1,772.54 |
546.76 |
63.47 |
401 |
|
|
|
Liquidmetal Technologies Inc
|
122.92 |
0.97 |
-1.77 |
18 |
|
The revenue of Liquidmetal Technologies Inc does not correlate significantly with that of Baxter International Inc . The correlation coefficient is 0.063 |
|
Veeva Systems Inc
|
46,924.78 |
2,472.14 |
592.23 |
7,291 |
|
Veeva Systems Inc 's revenue correlates notably with that of Baxter International Inc . The correlation coefficient is 0.462 |
| SUBTOTAL |
475,850.44 |
316,140.89 |
22,522.92 |
301,535 |
News about
Baxter International Inc Contracts
|
Baxter International Inc. has recently received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication of its proprietary product, Clinolipid (Lipid Injectable Emulsion), in pediatric patients. This includes both preterm and term neonates, making Baxter a frontrunner in providing essential nutrition therapy for infants when oral or enteral nutrition is not possible. Furthermore, despite experiencing fluctuations in sales and cost of sales in the first quarter of 2024, Baxter s suppliers have shown a promising year-on-year increase of 5.96%. This article will delve into the impact of these developments on Baxter International Inc. and the implications for its future performance.E...
|
Sharesource Remote Patient Management Platform Shows Promising Results in Reducing Home Dialysis Technique Failure
DEERFIELD, Ill. - In a breakthrough announcement, Baxter International Inc. (NYSE:BAX) has unveiled new data suggesting that its Sharesource remote patient management (RPM) digital platform, used in conjunction with an automated peritoneal dialysis (PD) system, is associated with a remarkable 77% reduction in the risk of PD technique failure. This groundbreaking development offers hope and improved outcomes for patients undergoing home dialysis.
Technique failure in peritoneal dialysis can occur due to various factors, resulting in patients needing to switch to in-center dialysis. Howeve...
|
|
63.01 % 